Sunshine Lake Pharma Becomes First Chinese Company to Secure FDA Approval for Insulin Glargine in US Market
Key Insights
Sunshine Lake Pharma received FDA approval for its insulin glargine injection Langlara (search), becoming the first Chinese company to enter the US insulin glargine market.
The product received interchangeable designation, allowing pharmacists to substitute it for Sanofi's Lantus without requiring new prescriptions from doctors.
The company secured an initial order of at least 18 million vials from US partner Lannett (search) over 18 months in the world's largest insulin market.
Sunshine Lake Pharma Co., Ltd. has achieved a historic milestone by becoming the first Chinese pharmaceutical company to receive FDA approval for an insulin glargine product in the United States. The company announced that its insulin glargine injection, marketed under the brand name Langlara (search), has secured marketing approval from the U.S. Food and Drug Administration.
Market Entry and Competitive Position
Langlara (search) becomes only the fourth insulin glargine product available in the US market, joining established offerings from global pharmaceutical giants Novo Nordisk, Sanofi, and Eli Lilly. The product is indicated for glycemic control in adults and pediatric patients with type 1 diabetes, and in adult patients with type 2 diabetes.
Significantly, the FDA approval includes interchangeable status, representing the highest standard for biosimilar drugs. This designation allows pharmacists to substitute Langlara (search) for the reference drug, Lantus® by Sanofi, without requiring prescriber intervention—a substantial competitive advantage in the marketplace.
Commercial Partnership and Market Opportunity
The company has established an exclusive distribution agreement with Lannett (search), a leading US pharmaceutical distributor, which has already placed an initial order for at least 18 million units over the next 18 months. This partnership provides immediate commercial traction and revenue security for Sunshine Lake Pharma's US market entry.
The US represents the world's largest insulin market, with annual spending exceeding $400 billion and accounting for nearly 80% of global sales. The insulin glargine segment specifically holds an estimated value of nearly $10 billion, with the US market representing over 60% of global share.
Clinical Development and Regulatory Validation
The FDA approval was supported by a Phase I overseas clinical trial that demonstrated strong biosimilarity to Sanofi's Lantus® in both pharmacokinetics and pharmacodynamics. The study was conducted in healthy male volunteers and enrolled 104 subjects, with 94 completing the key pharmacokinetic and pharmacodynamic study arms.
Sunshine Lake Pharma successfully passed an FDA on-site inspection conducted between September and October 2025, further validating the company's manufacturing standards and regulatory compliance.
Manufacturing Capabilities and Global Strategy
The company's Yidu Base maintains substantial production capacity, manufacturing over 100 million units of insulin products annually and covering second- to fourth-generation insulin products. This capacity is set to expand to 180 million vials to support growing demand.
Sunshine Lake Pharma has invested more than 2 billion yuan ($280 million) in its insulin business since beginning development in 2008. The company adopted a strategic approach of entering emerging markets before targeting the US and Europe, with insulin products already approved in the United Arab Emirates, Algeria, and Mali.
Global Expansion Prospects
The FDA approval is expected to serve as a catalyst for accelerated market entry into multiple emerging regions. The company anticipates faster regulatory approvals and market penetration in the Middle East, Southeast Asia, South America, West Africa, Brazil, Argentina, Indonesia, and Turkey.
Industry analysts note that the approval comes at a time when major insulin manufacturers face increasing pressure to lower prices in the US market, creating opportunities for lower-cost alternatives like Langlara (search).
Pipeline Development
Beyond the current approval, Sunshine Lake Pharma is advancing development of aspart insulin for the US market, with a regulatory decision expected in 2028. The company continues to explore additional commercialization channels and product opportunities in the competitive diabetes treatment landscape.
Domestically, all five of the company's insulin biosimilar products are approved and selected for China's National Volume-Based Procurement, providing a strong foundation in the home market to support international expansion efforts.